BETHESDA, Md. — Inspections by the FDA’s Office of Bioresearch Monitoring Operations (BIMO) will soon become more consistent from one trial site to another thanks to a major program alignment, says BIMO’s deputy director.
FDA staffers are currently being trained and more consistent reviews should be fully in place by 2020, David Glasgow told last week’s 13th Annual FDA Inspections Summit hosted by FDAnews.